好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluating U.S. Neurologists' Knowledge of New Anti-Epileptic Drug Safety Risks
Epilepsy/Clinical Neurophysiology (EEG)
S48 - (-)
005
The FDA monitors drug safety reports from manufacturers, researchers, and clinicians and then transmits clinically significant findings in "Drug Safety Communications" and "MedWatch Alert" emails. Despite these methods of communicating risks, it is unclear how frequently neurologists learn of updated antiepilepsy drug safety information, how neurologists learn of the risks, and if this information is incorporated into their practices.
We surveyed U.S. neurologists via the Internet on their knowledge of four recently announced AED safety risks and determined whether they altered patient care as a result.
Survey respondents (N = 505) reflected the 好色先生 demographics for active neurologists. Approximately 20% of neurologists were not aware of four major drug safety risks: suicidality with newer AEDs, increased birth defect risks and impaired cognitive development from in utero divalproex exposure and the requirement of haplotype screening in patients of Asian descent starting carbamazepine. While most neurologists were aware of a requirement for haplotype screening, many (77.5%) did not perform the safety screening and 18 reported patients having hypersensitivity reactions from carbamazepine treatment. Neurologists learned about drug safety risks from many sources; only notifications from specialty organizations were associated with an accurate knowledge of safety risks.
Although the majority of neurologists are aware of new AED safety risks, approximately 20% do not recognize these risks and many neurologists do not perform recommended safety procedures. Neurologists receive drug safety information non-systematically from multiple sources. Most would prefer implementing "a formal warning process via specialty organizations" and emails with updated product insert warnings directed to specialists.
Authors/Disclosures
Susan Shaw, MD
PRESENTER 		No disclosure on file
No disclosure on file
Martin E. Sanders, MD No disclosure on file
No disclosure on file
Jason Brandt, PhD (Johns Hopkins School of Med) No disclosure on file
Gregory Krauss, MD (Johns Hopkins University) Dr. Krauss has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvelle. Dr. Krauss has received stock or an ownership interest from EpiWatch.